BRPI0817108B8 - composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma. - Google Patents

composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.

Info

Publication number
BRPI0817108B8
BRPI0817108B8 BRPI0817108A BRPI0817108A BRPI0817108B8 BR PI0817108 B8 BRPI0817108 B8 BR PI0817108B8 BR PI0817108 A BRPI0817108 A BR PI0817108A BR PI0817108 A BRPI0817108 A BR PI0817108A BR PI0817108 B8 BRPI0817108 B8 BR PI0817108B8
Authority
BR
Brazil
Prior art keywords
composition
kit
fusion protein
chimeric moieties
certain embodiments
Prior art date
Application number
BRPI0817108A
Other languages
English (en)
Portuguese (pt)
Inventor
Xuan Caiyun
L Morrison Sherie
Huang Tzu-Hsuan
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0817108A2 publication Critical patent/BRPI0817108A2/pt
Publication of BRPI0817108B1 publication Critical patent/BRPI0817108B1/pt
Publication of BRPI0817108B8 publication Critical patent/BRPI0817108B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0817108A 2007-09-21 2008-09-19 composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma. BRPI0817108B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99471707P 2007-09-21 2007-09-21
PCT/US2008/077074 WO2009039409A1 (en) 2007-09-21 2008-09-19 Targeted interferon demonstrates potent apoptotic and anti-tumor activities

Publications (3)

Publication Number Publication Date
BRPI0817108A2 BRPI0817108A2 (pt) 2015-03-31
BRPI0817108B1 BRPI0817108B1 (pt) 2020-04-22
BRPI0817108B8 true BRPI0817108B8 (pt) 2021-05-25

Family

ID=40468388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817108A BRPI0817108B8 (pt) 2007-09-21 2008-09-19 composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.

Country Status (12)

Country Link
US (5) US9139634B2 (enExample)
EP (3) EP2853267B1 (enExample)
JP (3) JP5591701B2 (enExample)
KR (2) KR101759460B1 (enExample)
CN (3) CN103880965B (enExample)
AU (1) AU2008302111B2 (enExample)
BR (1) BRPI0817108B8 (enExample)
CA (1) CA2699944C (enExample)
ES (1) ES2536772T3 (enExample)
IL (2) IL204644A (enExample)
MX (2) MX2010003099A (enExample)
WO (1) WO2009039409A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
CN103880965B (zh) 2007-09-21 2018-02-16 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
AU2011268356B2 (en) * 2010-06-16 2013-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
EP2718328A4 (en) * 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
CN104144949B (zh) 2011-12-22 2016-08-31 财团法人生物技术开发中心 双特异性t细胞活化剂抗体
ES2694180T3 (es) * 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
WO2013134138A1 (en) * 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
CA2947354C (en) * 2012-04-30 2024-03-19 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
DK2857420T3 (da) 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd Målvævsspecifikt antigenbindende molekyle
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2014028502A1 (en) * 2012-08-13 2014-02-20 ImmunGene Inc. Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
MX2015002269A (es) * 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
UA113129C2 (xx) 2013-04-29 2016-12-12 ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
ES2780948T3 (es) * 2013-07-11 2020-08-27 Scripps Research Inst Proteínas de fusión de inmunoglobulinas en hélice enrollada y composiciones de las mismas
DK3299466T3 (da) * 2013-07-18 2019-11-18 Vib Vzw Fusokiner, der involverer cytokiner med kraftigt reducerede receptorbindingsaffiniteter
US9914759B2 (en) 2013-07-19 2018-03-13 Vib Vzw Targeted modified TNF family members
CN105612180B (zh) 2013-07-19 2019-11-12 弗拉芒区生物技术研究所 经靶向修饰的il-1家族成员
MX375426B (es) 2013-07-19 2025-03-06 Vib Vzw Direccionamiento de antagonistas de citocinas.
WO2015021444A1 (en) * 2013-08-09 2015-02-12 The Trustees Of The University Of Pennsylvania Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
KR102339240B1 (ko) * 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
EP3078744B1 (en) 2013-12-04 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
EP3139955B1 (en) 2014-04-30 2024-03-20 President and Fellows of Harvard College Fusion proteins for treating cancer and related methods
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
EP3221351B1 (en) * 2014-11-19 2024-11-13 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
US20170002057A1 (en) * 2015-02-26 2017-01-05 Nal Pharmaceutical Group Limited Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same
US20210009720A1 (en) * 2015-03-03 2021-01-14 Genopharm Inc. Human interferon-beta variant conjugated immunocytokine and method for preparing same
KR101838919B1 (ko) * 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3307301A4 (en) * 2015-06-12 2019-04-10 ImmunGene, Inc. FOCUSED INTERFERON IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
JP6452577B2 (ja) * 2015-08-27 2019-01-16 株式会社沖データ 画像形成装置
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US10919950B2 (en) 2016-01-14 2021-02-16 Seattle Children's Hospital Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CA3013558C (en) 2016-02-05 2024-11-12 Universiteit Gent CD8 LIAISON OFFICERS
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017180764A1 (en) * 2016-04-12 2017-10-19 Immungene, Inc. Focused interferon immunotherapy
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, MULTIMERIZING STRADOMER
RU2766582C2 (ru) 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
KR102793204B1 (ko) 2017-08-09 2025-04-08 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
CN111328286B (zh) 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
US12415843B2 (en) 2018-03-19 2025-09-16 The Regents Of The University Of California Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
CN118754986A (zh) 2018-08-10 2024-10-11 中外制药株式会社 抗cd137抗原结合分子及其应用
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
CN114072164A (zh) * 2019-03-06 2022-02-18 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
JP7689079B2 (ja) * 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
US11136353B2 (en) 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
JP2023503258A (ja) * 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
EP4069291A1 (en) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-associated antigen binding proteins and uses thereof
EP4142786A4 (en) * 2020-04-27 2024-06-19 Ohio State Innovation Foundation LIVE ATTENUATED MEASLES VIRUS VACCINE AGAINST SARS-COV-2
IL300062A (en) 2020-07-20 2023-03-01 Deka Biosciences Inc Dual fused cytokine proteins containing IL-10
JP2024534257A (ja) * 2021-08-12 2024-09-18 上海才致薬成生物科技有限公司 二重特異性組換えタンパク質及びその使用
KR20240015037A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 Vc1 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
CN120051483A (zh) 2022-08-18 2025-05-27 再生元制药公司 干扰素前蛋白及其用途
AU2024274130A1 (en) 2023-05-12 2026-01-08 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
WO2025106883A1 (en) * 2023-11-15 2025-05-22 President And Fellows Of Harvard College Engineered fc-prolactin fusions to increase lactation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
CA1336076C (en) 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5976531A (en) 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5844093A (en) 1994-03-17 1998-12-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Anti-EGFR single-chain Fvs and anti-EGFR antibodies
PT706799E (pt) 1994-09-16 2002-05-31 Merck Patent Gmbh Imunoconjugados ii
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
AU706056B2 (en) * 1995-10-13 1999-06-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxin containing a disulfide-stabilized antibody fragment
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
EA002474B1 (ru) * 1996-02-20 2002-06-27 Апплайд Резеч Системз Арс Холдинг Н.В. Гибридный белок, образующий гетеродимеры, способ его получения и использования
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CN1325115C (zh) * 1998-10-05 2007-07-11 法麦克萨有限公司 Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2001079444A2 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
CA2412901A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceutical Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
DK1724284T3 (da) 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20020193569A1 (en) 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
AU2003208415B2 (en) 2002-02-14 2009-05-28 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US7736652B2 (en) * 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US20070003514A1 (en) 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
US7456257B2 (en) * 2003-02-18 2008-11-25 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
WO2005021710A2 (en) * 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
WO2006107617A2 (en) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
SI2471813T1 (sl) * 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
AU2005266184A1 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
RU2007130552A (ru) * 2005-01-10 2009-02-20 Рисерч Дивелопмент Фаундейшн (US) Рекомбинантные молекулы направленного действия для лечения рака
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
ES2436761T3 (es) * 2005-06-29 2014-01-07 Yeda Research And Development Co., Ltd. Mutantes de interferón alfa 2 (IFN alfa 2) recombinante
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay
EP1951757B1 (en) 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
CN103880965B (zh) * 2007-09-21 2018-02-16 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US20100047164A1 (en) 2008-04-11 2010-02-25 Duke University Anti-Tumor Antibodies
WO2009134870A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Potent cell-binding agent drug conjugates
WO2010033866A2 (en) 2008-09-19 2010-03-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
RU2015128833A (ru) 2009-05-06 2015-11-10 Биотест Аг Применения иммуноконъюгатов, мишенью которых является cd138
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
WO2012075327A1 (en) 2010-12-02 2012-06-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods for treating a tumor using an antibody that specifically binds grp94
BR112013019083A2 (pt) 2011-02-10 2017-04-04 Roche Glycart Ag combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
US9783613B2 (en) 2011-10-04 2017-10-10 Igem Therapeutics Limited IgE anti-HMW-MAA antibody
WO2013134138A1 (en) * 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy

Also Published As

Publication number Publication date
BRPI0817108B1 (pt) 2020-04-22
US9139634B2 (en) 2015-09-22
EP2200634B1 (en) 2015-02-11
EP2853267A1 (en) 2015-04-01
CN108129573A (zh) 2018-06-08
EP2200634A1 (en) 2010-06-30
JP6087871B2 (ja) 2017-03-01
JP2010540453A (ja) 2010-12-24
IL233305A0 (en) 2014-08-31
CN101868246A (zh) 2010-10-20
US8258263B2 (en) 2012-09-04
CA2699944A1 (en) 2009-03-26
KR101661770B1 (ko) 2016-10-04
US20100172868A1 (en) 2010-07-08
CN103880965B (zh) 2018-02-16
ES2536772T3 (es) 2015-05-28
US20110104112A1 (en) 2011-05-05
AU2008302111B2 (en) 2014-04-24
KR20100084634A (ko) 2010-07-27
MX2010003099A (es) 2010-05-17
KR20160063429A (ko) 2016-06-03
US20140079668A1 (en) 2014-03-20
EP2853267B1 (en) 2016-12-07
JP2017031215A (ja) 2017-02-09
US20170151342A1 (en) 2017-06-01
IL204644A0 (en) 2010-11-30
EP2200634A4 (en) 2012-05-30
US20100297076A1 (en) 2010-11-25
US9534033B2 (en) 2017-01-03
HK1199043A1 (en) 2015-06-19
CN108129573B (zh) 2021-10-08
EP3150218A1 (en) 2017-04-05
BRPI0817108A2 (pt) 2015-03-31
JP5591701B2 (ja) 2014-09-17
AU2008302111A1 (en) 2009-03-26
EP3150218B1 (en) 2021-09-08
IL204644A (en) 2014-07-31
IL233305B (en) 2018-07-31
WO2009039409A1 (en) 2009-03-26
CA2699944C (en) 2017-11-14
CN103880965A (zh) 2014-06-25
US8563692B2 (en) 2013-10-22
JP2014208701A (ja) 2014-11-06
MX349306B (es) 2017-07-19
US10182984B2 (en) 2019-01-22
KR101759460B1 (ko) 2017-07-18

Similar Documents

Publication Publication Date Title
BRPI0817108B8 (pt) composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
CL2011001214A1 (es) Dimero de proteina similar a anticuerpo que comprende un decimo dominio de fibronectina de tipo iii (10fn3) que se une a igf-ir; unido covalentemente o no covalentemente con un 10fn3 que se une a egfr; composicion farmacéutica que lo comprende; uso de dicha composicion para tratar transtornos hiperproliferativo.
CR9186A (es) Composiciones y procedimientos referidos a anticuerpos contra el receptor de igf-1
UY30497A1 (es) Proteinas de fusion comprendiendo una exendina-4, composiciones y aplicaciones
MX2007013759A (es) Agentes de union de esclerostina.
MX338754B (es) Anticuerpos humanos contra el factor tisular.
UY30324A1 (es) Proteinas de fusion del rage, formulaciones y métodos de uso
MX369679B (es) Conjugados de anticuerpo fármaco (adc) que enlazan a proteínas 191p4d12.
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
CR20120105A (es) Proteínas terapéuticas de unión a dll4
CL2011000117A1 (es) Anticuerpo de dominio (dab) que se unen a cd28 y previene la union de dicha proteina a cd80 y/o cd86; uso del anticuerpo para tratar una enfermedad inmune; y composicion farmaceutica que lo comprende.
CL2012003187A1 (es) Proteinas de union a il-1 beta humana y ala il-1 alfa humana; conjugado de dicha proteina de unión; composicion para la liberacion de una proteina de unión; composicion farmaceutica.
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
BRPI0710645A2 (pt) Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
UA115517C2 (uk) Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
CL2011001285A1 (es) Anticuerpo que se une a la angiopoyetina-2 humana (ang-2 o ang2 o angpt2); acido nucleico que lo codifica; vector de expresion recombinante; celula huesped; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
DK1791571T3 (da) Radiofluorinerede peptider
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF